Top

Published in:

01-12-2014 | Original Article

Association of interleukin-23 receptor gene polymorphisms with risk of bladder cancer in Chinese

Authors: Tielong Tang, Hui Xue, Shu Cui, Zhiyong Gong, Zhonghai Fei, Shulin Cheng, Chunyan Gui

Published in: Familial Cancer | Issue 4/2014

Abstract

To assess whether polymorphisms of the interleukin-23 receptor (IL23R) gene are associated with bladder transitional cell carcinoma because chronic inflammation contributes to bladder cancer and the IL23R is known to be critically involved in the carcinogenesis of various malignant tumors. 226 patients with bladder cancer and 270 age-matched controls were involved in the study. Polymerase chain reaction–restriction fragment length polymorphism was used for genotyping. Genotype distribution and allelic frequencies between patients and controls were compared. In all three single nucleotide polymorphisms of IL23R studied, the distribution of genotype and allele frequencies of rs10889677 differed significantly between patients and controls. The frequency of allele C of rs10889677 was significantly increased in cases compared with controls (0.2898 vs. 0.1833, odds ratio 1.818, 95 % confidence interval 1.349–2.449). The result indicates that IL23R may play an important role in the susceptibility of bladder cancer in Chinese population.

Siegel R, Naishadham D, Jemal A (2013) Cancer statistics, 2013. CA Cancer J Clin 63(1):11–30. doi:10.3322/caac.21166 PubMedCrossRef

Cresswell J, Robertson H, Neal DE, Griffiths TR, Kirby JA (2001) Distribution of lymphocytes of the alpha(E)beta(7) phenotype and E-cadherin in normal human urothelium and bladder carcinomas. Clin Exp Immunol 126(3):397–402PubMedCentralPubMedCrossRef

Leibovici D, Grossman HB, Dinney CP et al (2005) Polymorphisms in inflammation genes and bladder cancer: from initiation to recurrence, progression, and survival. J Clin Oncol 23(24):5746–5756. doi:10.1200/JCO.2005.01.598 PubMedCrossRef

Parham C, Chirica M, Timans J et al (2002) A receptor for the heterodimeric cytokine IL-23 is composed of IL-12Rbeta1 and a novel cytokine receptor subunit, IL-23R. J Immunol 168(11):5699–5708PubMedCrossRef

Kim TH, Hong JM, Oh B et al (2008) Association of polymorphisms in the Interleukin 23 receptor gene with osteonecrosis of femoral head in Korean population. Exp Mol Med 40(4):418–426PubMedCentralPubMedCrossRef

Huber AK, Jacobson EM, Jazdzewski K, Concepcion ES, Tomer Y (2008) Interleukin (IL)-23 receptor is a major susceptibility gene for Graves’ ophthalmopathy: the IL-23/T-helper 17 axis extends to thyroid autoimmunity. J Clin Endocrinol Metab 93(3):1077–1081. doi:10.1210/jc.2007-2190 PubMedCentralPubMedCrossRef

Sung IH, Kim TH, Bang SY et al (2009) IL-23R polymorphisms in patients with ankylosing spondylitis in Korea. J Rheumatol 36(5):1003–1005. doi:10.3899/jrheum.081121 PubMedCrossRef

Langowski JL, Zhang X, Wu L et al (2006) IL-23 promotes tumour incidence and growth. Nature 442(7101):461–465. doi:10.1038/nature04808 PubMedCrossRef

Chen J, Lu Y, Zhang H et al (2010) A nonsynonymous polymorphism in IL23R gene is associated with risk of gastric cancer in a Chinese population. Mol Carcinog 49(10):862–868. doi:10.1002/mc.20661 PubMedCrossRef

10.

Chien MH, Hsin CH, Chou LS et al (2012) Interleukin-23 receptor polymorphism as a risk factor for oral cancer susceptibility. Head Neck 34(4):551–556. doi:10.1002/hed.21779 PubMedCrossRef

11.

Wang L, Liu W, Jiang W et al (2012) A miRNA binding site single-nucleotide polymorphism in the 3′-UTR region of the IL23R gene is associated with breast cancer. PLoS ONE 7(12):e49823. doi:10.1371/journal.pone.0049823 PubMedCentralPubMedCrossRef

12.

Zhang Z, Zhou B, Zhang J et al (2010) Association of interleukin-23 receptor gene polymorphisms with risk of ovarian cancer. Cancer Genet Cytogenet 196(2):146–152. doi:10.1016/j.cancergencyto.2009.09.006 PubMedCrossRef

13.

Duerr RH, Taylor KD, Brant SR et al (2006) A genome-wide association study identifies IL23R as an inflammatory bowel disease gene. Science 314(5804):1461–1463. doi:10.1126/science.1135245 PubMedCrossRef

14.

Newton RC, Beral V, Weiss R, Imperial Cancer Research Fund (Great Britain) (1999) Infections and human cancer. Cold Spring Harbor Laboratory Press, Plainview

15.

Balkwill F, Mantovani A (2001) Inflammation and cancer: back to Virchow? Lancet 357(9255):539–545. doi:10.1016/S0140-6736(00)04046-0 PubMedCrossRef

16.

Macarthur M, Hold GL, El-Omar EM (2004) Inflammation and cancer II. Role of chronic inflammation and cytokine gene polymorphisms in the pathogenesis of gastrointestinal malignancy. Am J Physiol Gastrointest Liver Physiol 286(4):G515–G520. doi:10.1152/ajpgi.00475.2003 PubMedCrossRef

17.

Tsai FJ, Chang CH, Chen CC, Hsia TC, Chen HY, Chen WC (2005) Interleukin-4 gene intron-3 polymorphism is associated with transitional cell carcinoma of the urinary bladder. BJU Int 95(3):432–435. doi:10.1111/j.1464-410X.2005.05315.x PubMedCrossRef

18.

Marsh HP, Haldar NA, Bunce M et al (2003) Polymorphisms in tumour necrosis factor (TNF) are associated with risk of bladder cancer and grade of tumour at presentation. Br J Cancer 89(6):1096–1101. doi:10.1038/sj.bjc.6601165 PubMedCentralPubMedCrossRef

19.

Chen T, Jackson C, Costello B et al (2004) An intronic variant of the TGFBR1 gene is associated with carcinomas of the kidney and bladder. Int J Cancer 112(3):420–425. doi:10.1002/ijc.20419 PubMedCrossRef

20.

Kang S, Kim YB, Kim MH et al (2005) Polymorphism in the nuclear factor kappa-B binding promoter region of cyclooxygenase-2 is associated with an increased risk of bladder cancer. Cancer Lett 217(1):11–16. doi:10.1016/j.canlet.2004.06.053 PubMedCrossRef

21.

Pirhonen J, Matikainen S, Julkunen I (2002) Regulation of virus-induced IL-12 and IL-23 expression in human macrophages. J Immunol 169(10):5673–5678PubMedCrossRef

22.

Dunn GP, Bruce AT, Ikeda H, Old LJ, Schreiber RD (2002) Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol 3(11):991–998. doi:10.1038/ni1102-991 PubMedCrossRef

23.

Dunn GP, Old LJ, Schreiber RD (2004) The three Es of cancer immunoediting. Annu Rev Immunol 22:329–360. doi:10.1146/annurev.immunol.22.012703.104803 PubMedCrossRef

24.

Dunn GP, Old LJ, Schreiber RD (2004) The immunobiology of cancer immunosurveillance and immunoediting. Immunity 21(2):137–148. doi:10.1016/j.immuni.2004.07.017 PubMedCrossRef

25.

Langowski JL, Kastelein RA, Oft M (2007) Swords into plowshares: IL-23 repurposes tumor immune surveillance. Trends Immunol 28(5):207–212. doi:10.1016/j.it.2007.03.006 PubMedCrossRef

26.

Numasaki M, Fukushi J, Ono M et al (2003) Interleukin-17 promotes angiogenesis and tumor growth. Blood 101(7):2620–2627. doi:10.1182/blood-2002-05-1461 PubMedCrossRef

27.

Du JW, Xu KY, Fang LY, Qi XL (2012) Interleukin-17, produced by lymphocytes, promotes tumor growth and angiogenesis in a mouse model of breast cancer. Mol Med Rep 6(5):1099–1102. doi:10.3892/mmr.2012.1036 PubMed

28.

McKenzie BS, Kastelein RA, Cua DJ (2006) Understanding the IL-23-IL-17 immune pathway. Trends Immunol 27(1):17–23. doi:10.1016/j.it.2005.10.003 PubMedCrossRef

29.

Chen B, Zeng Z, Xu L et al (2011) IL23R +2199A/C polymorphism is associated with decreased risk of certain subtypes of gastric cancer in Chinese: a case–control study. Cancer Epidemiol 35(2):165–169. doi:10.1016/j.canep.2010.08.006 PubMedCrossRef

30.

Cole SW (2009) Chronic inflammation and breast cancer recurrence. J Clin Oncol 27(21):3418–3419. doi:10.1200/JCO.2009.21.9782 PubMedCrossRef

Title: Association of interleukin-23 receptor gene polymorphisms with risk of bladder cancer in Chinese
Authors: Tielong Tang
Hui Xue
Shu Cui
Zhiyong Gong
Zhonghai Fei
Shulin Cheng
Chunyan Gui
Publication date: 01-12-2014
Publisher: Springer Netherlands
Published in: Familial Cancer / Issue 4/2014
Print ISSN: 1389-9600
Electronic ISSN: 1573-7292
DOI: https://doi.org/10.1007/s10689-014-9731-6

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 4/2014

Association of reduced XRCC2 expression with lymph node metastasis in breast cancer tissues

Hereditary leiomyomatosis and renal cell cancer (HLRCC): renal cancer risk, surveillance and treatment

High prevalence of mismatch repair deficiency in prostate cancers diagnosed in mismatch repair gene mutation carriers from the colon cancer family registry

“It’s all very well reading the letters in the genome, but it’s a long way to being able to write”: Men’s interpretations of undergoing genetic profiling to determine future risk of prostate cancer

Muir–Torre syndrome or phenocopy? The value of the immunohistochemical expression of mismatch repair proteins in sebaceous tumors of immunocompromised patients

A polymorphism at miRNA-122-binding site in the IL-1α 3′UTR is associated with risk of epithelial ovarian cancer

Keynote webinar | Spotlight on antibody–drug conjugates in cancer